Precise targeting of osteopontin in non-small cell lung cancer spinal metastasis to promote chemosensitivity via a smart hollow nano-platform

Lei Zhou,Hong-Jun Zhuang,Qing Chen,Li-Ping Jiang,Xue-Min Han,Yu-Xiang Ge,Tai-Wei Zhang,Hai-Feng Liang,Wang Ding,Ming Qi,Jian Dong,Tao Yi,Li-Bo Jiang
DOI: https://doi.org/10.1016/j.cej.2021.132131
IF: 15.1
2022-05-01
Chemical Engineering Journal
Abstract:Resistance to chemotherapy is a key factor affecting Non-small cell lung cancer spinal metastasis (NSCLC-SM) treatment efficiency. In this study, Osteopontin (OPN), an intracellular and a secreted glycoprotein, showed overexpression in NSCLC-SM. Further studies demonstrated that OPN promoted chemoresistance by activating mTORC2/AKT/NF-κB/MDR1 signaling via interaction with integrin αvβ3. Subsequently, it was confirmed that a specific inhibitor of OPN/αvβ3, the pentapeptide Gly-Arg-Gly-Asp-Ser (TFA), targeted NSCLC-SM and promoted chemosensitivity by competitively blocking the OPN/αvβ3 interaction and by inhibiting the downstream signaling. Therefore, a TFA-modified and cisplatin (DDP)-loaded hollow MnO2 structure (H-MnO2/DDP(Cy)-TFA nanocapsules) was fabricated in the present study. The H-MnO2/DDP(Cy)-TFA targeted OPN, exhibited responses to the tumor microenvironment, and demonstrated high drug loading and controlled release. In a NSCLC-SM mouse model, H-MnO2/DDP(Cy)-TFA enhanced chemosensitivity and suppressed tumor progression via combination effect of targeted inhibition of OPN and controlled release of DDP. Collectively, the present study elucidated the mechanism underlying OPN-mediated NSCLC chemoresistance and a nano-drug delivery platform was developed as a new therapeutic strategy for precisely targeting NSCLC-SM and for enhancing chemosensitivity.
engineering, chemical, environmental
What problem does this paper attempt to address?